Desy Fitrya Syamsumir

Desy Fitrya Syamsumir

Auto-generated profile, based on publicly available information

Desy Fitrya Syamsumir

Institute of Marine Biotechnology Universiti Malaysia Terengganu Kuala Nerus 21030 Terengganu Malaysia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Saudi Journal of Biological Sciences
Verified
Journal Article
Open access
IPInten Pangestika
Inten Pangestika
EOEfriyana Oksal
Efriyana Oksal
TMTengku Sifzizul Tengku Muhammad
Tengku Sifzizul Tengku Muhammad
HAHermansyah Amir
Hermansyah Amir
DSDesy Fitrya Syamsumir
Desy Fitrya Syamsumir
YAYosie Andriani
Yosie Andriani
One of the pathways to reduce cholesterol production in the liver is through the inhibition of HMG-Coa reductase (HMGCR) by current drugs, statins. However, these have side effects if consumed in prolonged periods. Tangeretin and trans-ethyl caffeate as alternative drugs in reducing hypercholesterolemia and preventing atherosclerosis have never been reported. Their effects on inhibiting HMGCR activity were investigated through enzymatic method (in vitro and in vivo). The toxicity property was analyzed on the Serum Glutamate Oxalate Transaminase (SGOT)/Serum Glutamate Piruvate Transaminase (SGPT) levels and rat liver histology. The results showed that both compounds inhibited HMGCR activity significantly compare to the control simvastatin (p < 0.05). Tangeretin which showed very good activity in inhibiting HMGCR (83.8 of % inhibition, equal to simvastatin) was selected and used for anti-hypercholesterolemia in vivo assessment. Furthermore, tangeretin was shown to effectively reduced Total Cholesterol (TC) and Low Density Lipoprotein (LDL), and increased High Density Lipoprotein (HDL) levels significantly compared to the simvastatin group (p < 0.05). Tangeretin group was also proven to inhibit HMGCR rat liver activity significantly compare to the control simvastatin (p < 0.05). The toxicity study on the SGOT/SGPT levels and liver histology revealed that there were no side effects after administration by tangeretin. Results found that both tangeretin and trans-ethyl caffeate are potent candidates as anti-hypercholesterolemia agent in vitro. In addition, tangeretin was also shown to be safe and suitable as an alternative treatment for controlling hypercholesterolemia in vivo as well as have potency for preventing atherosclerosis.

9 March 2015 in Molecules
Verified
Journal Article
Open access
PDF file
YAYosie Andriani
Yosie Andriani
TMTengku Sifzizul Tengku Muhammad
Tengku Sifzizul Tengku Muhammad
HMHabsah Mohamad
Habsah Mohamad
JSJasnizat Saidin
Jasnizat Saidin
DSDesy Fitrya Syamsumir
Desy Fitrya Syamsumir
MWMohd Effendy Abd Wahid
Mohd Effendy Abd Wahid
In vitro and in vivo studies of the activity of Phaleria macrocarpa Boerl (Thymelaeaceae) leaves against the therapeutic target for hypercholesterolemia were done using the HDL receptor (SR-BI) and hypercholesterolemia-induced Sprague Dawley rats. The in vitro study showed that the active fraction (CF6) obtained from the ethyl acetate extract (EMD) and its component 2',6',4-trihydroxy-4'-methoxybenzophenone increased the SR-BI expression by 95% and 60%, respectively. The in vivo study has proven the effect of EMD at 0.5 g/kgbw dosage in reducing the total cholesterol level by 224.9% and increasing the HDL cholesterol level by 157% compared to the cholesterol group. In the toxicity study, serum glutamate oxalate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) activity were observed to be at normal levels. The liver histology also proved no toxicity and abnormalities in any of the treatment groups, so it can be categorized as non-toxic to the rat liver. The findings taken together show that P. macrocarpa leaves are safe and suitable as an alternative control and prevention treatment for hypercholesterolemia in Sprague Dawley rats.

4 January 2023 in Progress In Microbes & Molecular Biology
Verified
Journal Article
Open access
PDF file
AZAhmad Zulkefly
Ahmad Zulkefly
WAWan Norlina Wan Azman
Wan Norlina Wan Azman
JOJulia Omar
Julia Omar
NMNurul Syakima Ab Mutalib
Nurul Syakima Ab Mutalib
DSDesy Fitrya Syamsumir
Desy Fitrya Syamsumir
TDTengku Ahmad Damitri Al-Astani Tengku Din
Tengku Ahmad Damitri Al-Astani Tengku Din
This case-control study, conducted at the Hospital USM BestARi unit, aimed to identify the serum metabolic fingerprint among individuals with breast lumps and healthy controls, and to discover potential biomarkers. Serum samples from healthy controls, benign breast lump patients, and malignant breast lump patients were analyzed using proton nuclear magnetic resonance spectroscopy (1H NMR). A multivariate data analysis approach was employed, with the OPLS-DA and clustered heat map techniques effectively differentiating between the three groups. The study revealed significant metabolite variations across the groups and proposed D-glucose, glycerol, and glycine as potential biomarkers for breast cancer diagnosis. Metabolic pathways such as alanine, aspartate, glutamate metabolism, and glycine, serine, and threonine metabolism were implicated. The metabolomics approach coupled with multivariate analysis successfully identified key metabolites leading to group separation and suggested altered metabolic pathways. However, further research and integration with other ‘omics’ technologies are necessary for clinical translation.